Anti-ARH antibody - Carboxyterminal end (ab63155)

Overview

  • Product nameAnti-ARH antibody - Carboxyterminal end
    See all ARH primary antibodies
  • Description
    Rabbit polyclonal to ARH - Carboxyterminal end
  • Tested applicationsWB, ELISA, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide (Human) conjugated to KLH to the C terminal region of human ARH.

  • Positive control
    • NCI-H460 cell line lysates and human hepatocarcinoma tissue.

Properties

Applications

Our Abpromise guarantee covers the use of ab63155 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/50 - 1/100. Detects a band of approximately 36 kDa (predicted molecular weight: 34 kDa).
ELISA 1/1000.
IHC-P 1/50.

Target

  • FunctionAdapter protein (clathrin-associated sorting protein (CLASP)) required for efficient endocytosis of the LDL receptor (LDLR) in polarized cells such as hepatocytes and lymphocytes, but not in non-polarized cells (fibroblasts). May be required for LDL binding and internalization but not for receptor clustering in coated pits. May facilitate the endocytocis of LDLR and LDLR-LDL complexes from coated pits by stabilizing the interaction between the receptor and the structural components of the pits. May also be involved in the internalization of other LDLR family members. Binds to phosphoinositides, which regulate clathrin bud assembly at the cell surface.
  • Tissue specificityExpressed at high levels in the kidney, liver, and placenta, with lower levels detectable in brain, heart, muscle, colon, spleen, intestine, lung, and leukocytes.
  • Involvement in diseaseDefects in LDLRAP1 are the cause of autosomal recessive hypercholesterolemia (ARH) [MIM:603813]. ARH is a disorder caused by defective internalization of LDL receptors (LDLR) in the liver. ARH has the clinical features of familial hypercholesterolemia (FH) [MIM:143890] homozygotes, including severely elevated plasma LDL cholesterol, tuberous and tendon xanthomata, and premature atherosclerosis. LDL receptor (LDLR) activity measured in skin fibroblasts is normal, as the LDL binding ability.
  • Sequence similaritiesContains 1 PID domain.
  • DomainThe [DE]-X(1,2)-F-X-X-[FL]-X-X-X-R motif mediates interaction the AP-2 complex subunit AP2B1.
  • Post-translational
    modifications
    Phosphorylated upon DNA damage, probably by ATM or ATR.
  • Cellular localizationCytoplasm.
  • Information by UniProt
  • Database links
  • Alternative names
    • ARH antibody
    • ARH GENE antibody
    • ARH_HUMAN antibody
    • ARH1 antibody
    • ARH2 antibody
    • Autosomal recessive hypercholesterolemia protein antibody
    • DKFZp586D0624 antibody
    • FHCB1 antibody
    • FHCB2 antibody
    • LDL receptor adaptor protein antibody
    • Ldlrap1 antibody
    • Low density lipoprotein receptor adapter protein 1 antibody
    • MGC34705 antibody
    • OTTHUMP00000008526 antibody
    see all

Anti-ARH antibody - Carboxyterminal end images

  • Anti-ARH antibody - Carboxyterminal end (ab63155) at 1/60 dilution + NCI-H460 cell line lysates at 35 µg

    Predicted band size : 34 kDa
    Observed band size : 36 kDa (why is the actual band size different from the predicted?)
  • Immunohistochemical analysis of ARH expression in formalin fixed, paraffin embedded human hepatocarcinoma tissue using 1/50 ab63155, followed by peroxidase-conjugated secondary antibody step and DAB staining.

References for Anti-ARH antibody - Carboxyterminal end (ab63155)

ab63155 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab63155.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"